gabexate has been researched along with Glomerulonephritis in 3 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Glomerulonephritis: Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of camostat mesilate (CM), a derivative of gabexate mesilate developed for oral use, on primary glomerulonephritis (GN) and chance hematuria and/or proteinuria were evaluated." | 9.11 | Effect of oral camostat mesilate on hematuria and/or proteinuria in children. ( Asami, T; Tomisawa, S; Uchiyama, M, 2004) |
| "Camostat mesilate, a developed derivative of gabexate mesilate for oral use, was administered in a daily dose of 600 mg for 4 weeks to 17 patients with heavy proteinuria due to various nephropathies." | 7.67 | Effect of camostat mesilate on heavy proteinuria in various nephropathies. ( Futaki, G; Hotta, O; Kurosawa, K; Matsubara, M; Suzuki, K; Taguma, Y, 1989) |
| "The effects of camostat mesilate (CM), a derivative of gabexate mesilate developed for oral use, on primary glomerulonephritis (GN) and chance hematuria and/or proteinuria were evaluated." | 5.11 | Effect of oral camostat mesilate on hematuria and/or proteinuria in children. ( Asami, T; Tomisawa, S; Uchiyama, M, 2004) |
| "Effect of serine protease inhibitor Camostat Mesilate (Foipan) on primary glomerulonephritis and it's mechanism were evaluated." | 3.68 | [Effect of protease inhibitor on primary glomerulonephritis and the mechanism of the effect]. ( Fukushima, M; Haramoto, T; Kumagai, I; Makino, H; Murakami, K; Ogura, T; Onbe, T; Ota, Z; Wada, J, 1991) |
| "Camostat mesilate, a developed derivative of gabexate mesilate for oral use, was administered in a daily dose of 600 mg for 4 weeks to 17 patients with heavy proteinuria due to various nephropathies." | 3.67 | Effect of camostat mesilate on heavy proteinuria in various nephropathies. ( Futaki, G; Hotta, O; Kurosawa, K; Matsubara, M; Suzuki, K; Taguma, Y, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asami, T | 1 |
| Tomisawa, S | 1 |
| Uchiyama, M | 1 |
| Onbe, T | 1 |
| Makino, H | 1 |
| Haramoto, T | 1 |
| Wada, J | 1 |
| Ogura, T | 1 |
| Kumagai, I | 1 |
| Murakami, K | 1 |
| Fukushima, M | 1 |
| Ota, Z | 1 |
| Matsubara, M | 1 |
| Taguma, Y | 1 |
| Kurosawa, K | 1 |
| Hotta, O | 1 |
| Suzuki, K | 1 |
| Futaki, G | 1 |
1 trial available for gabexate and Glomerulonephritis
| Article | Year |
|---|---|
Effect of oral camostat mesilate on hematuria and/or proteinuria in children.
Topics: Administration, Oral; Adolescent; Biopsy; Child; Child, Preschool; Esters; Female; Follow-Up Studies | 2004 |
2 other studies available for gabexate and Glomerulonephritis
| Article | Year |
|---|---|
[Effect of protease inhibitor on primary glomerulonephritis and the mechanism of the effect].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Urea Nitrogen; Complement System Proteins; Creatin | 1991 |
Effect of camostat mesilate on heavy proteinuria in various nephropathies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Esters; Female; Gabexate; Glomerulonephritis; Glycosu | 1989 |